These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24615549)

  • 1. Granisetron transdermal system improves refractory nausea and vomiting in gastroparesis.
    Simmons K; Parkman HP
    Dig Dis Sci; 2014 Jun; 59(6):1231-4. PubMed ID: 24615549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study.
    Midani D; Parkman HP
    J Neurogastroenterol Motil; 2016 Oct; 22(4):650-655. PubMed ID: 27400689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domperidone to Treat Symptoms of Gastroparesis: Benefits and Side Effects from a Large Single-Center Cohort.
    Schey R; Saadi M; Midani D; Roberts AC; Parupalli R; Parkman HP
    Dig Dis Sci; 2016 Dec; 61(12):3545-3551. PubMed ID: 27530760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroparesis-associated refractory nausea treated with aprepitant.
    Fahler J; Wall GC; Leman BI
    Ann Pharmacother; 2012 Dec; 46(12):e38. PubMed ID: 23191934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptomatic management for gastroparesis: antiemetics, analgesics, and symptom modulators.
    Hasler WL
    Gastroenterol Clin North Am; 2015 Mar; 44(1):113-26. PubMed ID: 25667027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal granisetron: a guide to its use in preventing nausea and vomiting induced by chemotherapy.
    Keating GM; Duggan ST; Curran MP
    CNS Drugs; 2012 Sep; 26(9):787-90. PubMed ID: 22834568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study.
    Yang LQ; Sun XC; Qin SK; Chen YX; Zhang HL; Cheng Y; Chen ZD; Shi JH; Wu Q; Bai YX; Han BH; Liu W; Ouyang XN; Liu JW; Zhang ZH; Li YQ; Xu JM; Yu SY
    Chin Clin Oncol; 2016 Dec; 5(6):79. PubMed ID: 28061543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
    Boccia RV; Gordan LN; Clark G; Howell JD; Grunberg SM;
    Support Care Cancer; 2011 Oct; 19(10):1609-17. PubMed ID: 20835873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day highly or moderately emetogenic chemotherapy: role of transdermal granisetron.
    Coluzzi F; Mattia C
    Future Oncol; 2016 Aug; 12(16):1865-76. PubMed ID: 27184113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-emetic effect of granisetron in patients undergoing cranial and craniospinal radiotherapy].
    Yamasaki F; Watanabe Y; Nosaka R; Kenjo M; Nakamura K; Takayasu T; Saito T; Tominaga A; Sugiyama K; Kurisu K
    No Shinkei Geka; 2014 Jan; 42(1):27-34. PubMed ID: 24388937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal versus oral granisetron in controlling chemotherapy-induced nausea and vomiting: a meta-analysis.
    Chua AV; Hernandez ARB; Real IO
    Support Care Cancer; 2020 Dec; 28(12):5611-5619. PubMed ID: 32623521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy.
    Silva RR; Bascioni R; Giorgi F; Acito L; Giustini L; De Signoribus G; Marcellini M; Menichetti ET; Giuliodori L
    Support Care Cancer; 1996 Jul; 4(4):287-90. PubMed ID: 8829306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraperitoneal ondansetron hydrochloride for intractable nausea and vomiting due to diabetic gastroparesis in a patient on peritoneal dialysis.
    Amin K; Bastani B
    Perit Dial Int; 2002; 22(4):539-40. PubMed ID: 12322834
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
    Kim JE; Hong YS; Lee JL; Kim KP; Park SJ; Sym SJ; Shin DB; Lee J; Park YS; Ahn JS; Kim TW
    Support Care Cancer; 2015 Jun; 23(6):1769-77. PubMed ID: 25465680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of transdermal granisetron in women with nausea and vomiting of pregnancy.
    Caritis S; Zhao Y; Chen HJ; Venkataramanan R
    Am J Obstet Gynecol; 2016 Jul; 215(1):93.e1-4. PubMed ID: 26812081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of symptoms, syndrome and disease: treatment of refractory diabetic gastroparesis.
    Li JL; Li M; Pang B; Zhou Q; Tian JX; Liu HX; Zhao XY; Tong XL
    World J Gastroenterol; 2014 Jul; 20(26):8674-80. PubMed ID: 25024625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy.
    Sigsgaard T; Herrstedt J; Christensen P; Andersen O; Dombernowsky P
    Support Care Cancer; 2000 May; 8(3):233-7. PubMed ID: 10789966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.